Strides Pharma Science has reported a net profit of Rs 68.3 crore in the first quarter of 2024-25 (Q1FY25). The firm had reported a loss of Rs 9.4 crore in the same quarter of the previous financial year (Q1FY4). In the fourth quarter of 2023-24 (Q4FY24), it had reported a net profit of Rs 10 crore. Which suggested that it has witnessed about 580 per cent sequential jump in its net profit.

The revenue for the Q1FY25 came in at Rs 1,085.7 crore, up 16.6 per cent YoY. 

Arun Kumar, Founder & Executive Chairperson, and Badree Komandur, MD & Group CEO, commented on the performance and said, “Our emphasis on profitability, efficiency and growth has led to a strong performance across markets, allowing us to deliver superior returns ahead of the projected timelines for our FY25 outlook. The company achieved critical thresholds of 20% EBITDA margin, Rs.68.3 crore of reported PAT and 2.3x Debt/EBITDA ratio. We are confident of sustaining the momentum with continuous improvement in the quality of business. The company has increased its focus on digitization, automation, and ESG for better compliance and business outcomes.”